Earnings summaries and quarterly performance for UNITED GUARDIAN.
Executive leadership at UNITED GUARDIAN.
Board of directors at UNITED GUARDIAN.
Research analysts covering UNITED GUARDIAN.
Recent press releases and 8-K filings for UG.
United-Guardian, Inc. Announces Third Quarter 2025 Financial Results
UG
Earnings
Demand Weakening
New Projects/Investments
- United-Guardian, Inc. reported a significant decline in Q3 2025 net sales to $2,264,261 from $3,060,113 in Q3 2024, with net income decreasing to $268,441 ($0.06 per share) from $865,484 ($0.19 per share).
- For the first nine months of 2025, net sales fell to $7,583,613 from $9,705,262 in 2024, and net income dropped to $1,456,162 ($0.32 per share) from $2,747,151 ($0.60 per share).
- The decrease was primarily driven by reduced purchases of cosmetic ingredients by Ashland Specialty Ingredients (ASI), attributed to tariff and geopolitical concerns in Asia, leading to customers opting for lower-cost local products and ASI managing excess inventory.
- Despite the overall decline, the company saw increased sales in pharmaceutical (10%) and medical products (6%) during the first nine months of 2025, and is pursuing initiatives like expanding Renacidin®'s formulary inclusion and new marketing agreements for personal care products to boost future revenue.
Nov 6, 2025, 2:00 PM
United Guardian Inc 2025 Annual Meeting & Conference Call Update (FY 2024, Q1 2025)
UG
Proxy Vote Outcomes
Auditor Change
New Projects/Investments
Share Buyback
- Governance & Proxy Vote Results: United Guardian Inc held its 2025 Annual Meeting on May 15, 2025, where stockholders voted on board elections (e.g., Ken Globus, Lawrence F. Maietta) and inspectors confirmed proxies represented 83% of outstanding shares .
- Meeting Outcomes: The meeting approved executive compensation proposals and ratified Grassi & Co., CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025 .
- Financial Performance: FY 2024 saw a 12% sales increase with improved retained earnings and stockholders’ equity, while Q1 2025 experienced mixed performance, including a decline in cosmetic ingredient sales .
- Tariff & Supply Chain Impact: Global tariff uncertainties, particularly extreme China tariffs, are driving up raw material costs even though major supply chain disruptions have not been reported .
- Forward Strategy & Product Pipeline: The company is focusing on expanding its pharmaceutical presence with initiatives for Renacidin, launching new products in sexual wellness and cosmetic ingredients, and reviewing key distributor contracts with Ashland while dismissing stock buybacks due to a small public float .
May 16, 2025, 12:00 AM
United-Guardian Reports Q1 2025 Results
UG
Earnings
Demand Weakening
- Net sales declined to $2.48M in Q1 2025 from $3.25M in Q1 2024, with net income dropping to $560.9K compared to $925.4K last year.
- Medical lubricant and pharmaceutical sales increased by 43% and 23% respectively, while cosmetic ingredient sales fell by 63%, primarily due to reduced orders from ASI.
- Management highlighted concerns over lingering tariff impacts and a slow start to 2025, emphasizing that the decrease in cosmetic ingredients was driven by excess inventory issues in China.
May 8, 2025, 12:00 AM
United-Guardian Reports Q4 2024 Financial Results
UG
Earnings
Revenue Acceleration/Inflection
- Net sales increased by 12% from $10.89M in FY 2023 to $12.18M in FY 2024, with net income rising from $2.58M to $3.25M and EPS improving from $0.56 to $0.71, indicating strong financial growth.
- Sales in key segments drove performance: cosmetic ingredients surged by 32% and medical lubricants by 16%, while pharmaceutical sales dipped by 5% due to supply issues with Renacidin impacting early 2024.
Mar 21, 2025, 12:00 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more